Pulmatrix (PULM) Current Deferred Revenue (2019 - 2024)
Pulmatrix (PULM) posted Current Deferred Revenue of $270000.0 for Q2 2024, down 25.62% sequentially from $363000.0 in Q1 2024, and down 75.65% YoY from $1.1 million in Q3 2023.
Pulmatrix (PULM) Current Deferred Revenue (2019 - 2024) Analysis & Trends
Pulmatrix has reported Current Deferred Revenue for 6 years, with the latest figure at $270000.0 in Q2 2024.
- Quarterly Current Deferred Revenue fell 75.65% year-over-year to $270000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $270000.0 (down 75.65% YoY) and the FY2023 annual result came in at $618000.0, down 53.85% from the prior year.
- Current Deferred Revenue retreated to $270000.0 in Q2 2024 per PULM's latest filing, from $363000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $12.0 million in Q1 2020 and troughed at $270000.0 in Q2 2024.
- A 5-year average of $2.7 million and a median of $1.4 million in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue plunged 89.82% in 2021, then jumped 42.6% in 2022.
- Over 5 years, Current Deferred Revenue stood at $4.2 million in 2020, then tumbled by 77.46% to $939000.0 in 2021, then jumped by 42.6% to $1.3 million in 2022, then tumbled by 53.85% to $618000.0 in 2023, then sank by 56.31% to $270000.0 in 2024.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $270000.0, $363000.0, and $618000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Dec 31, 2023 | 618,000.00 |
| Sep 30, 2023 | 988,000.00 |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Mar 31, 2022 | 1.52 Mn |
| Dec 31, 2021 | 939,000.00 |
| Sep 30, 2021 | 1.97 Mn |
| Jun 30, 2021 | 3.03 Mn |
| Mar 31, 2021 | 1.22 Mn |
| Dec 31, 2020 | 4.17 Mn |
| Sep 30, 2020 | 4.26 Mn |
| Jun 30, 2020 | 10.04 Mn |
| Mar 31, 2020 | 12.03 Mn |
| Dec 31, 2019 | 13.41 Mn |
| Sep 30, 2019 | 9.30 Mn |